1_ Porter et al. Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome  BMC Gastroenterology 2012, 12:55
2_N. Waugh, E. Cummins, P. Royle et al., “Faecal calprotectin
testing for differentiating amongst inflammatory and noninflammatory bowel diseases: systematic review and economic
evaluation,â€ Health Technology Assessment, vol. 17, no. 55, pp. 1–
211, 2013.
3_Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4. doi: 10.1016/j.cgh.2012.02.029. Epub 2012 Mar 15.
4_ J.A.Olmos,G.Iantorno. Irritable bowel syndrome: prevalence, comorbidity and impact: a population based study. UEGW 2010.
5_Agarwal N, Spiegel BM. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gastroenterol Clin North Am. 2011 Mar;40(1):11-9. doi: 10.1016/j.gtc.2010.12.013.
6_El-Serag HB, Pilgrim P, Schoenfeld P. Systemic Review: Natural history of irritable bowel syndrome. Aliment Pharmacol Ther. 2004 Apr 15;19(8):861-70.
7_Brian E. Lacy,1 Fermín Mearin, et al.Bowel Disorders.Gastroenterology 2016;150:1393–1407.
8_ Chey W, Nojkov B, Rubenstein J, et al. The yield of colonoscopy in patients
with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol 2010; 105: 859–65.
9_ Cash B, Schoenfeld P, Chey W. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol 2002; 97: 2812–9.
10_Rosa LS Soares.Irritable bowel syndrome: A clinical review.World J Gastroenterol 2014 September 14; 20(34): 12144-12160.
11_ Michael Camilleri, M.D. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012; 367:1626-1635 October 25, 2012. DOI: 10.1056/NEJMra1207068.
12_ Michael Camilleri, Karen Lasch and Wen Zhou. Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. The confluence of increased síndrome permeability, inflammation, and pain in irritable bowel. Am J Physiol Gastrointest Liver Physiol 303:G775-G785, 2012. First published 26 July 2012; doi: 10.1152/ajpgi.00155.2012.
13_Joseph D. Feuerstein, Adam S. Cheifetz,.Ulcerative Colitis: Epidemiology, Diagnosis, and Management. Mayo Clin Proc. 2014;89(11):1553-1563
14_Francis Ha, Hanan Khalil. Crohn’s disease: a clinical update. Ther Adv Gastroenterol2015, Vol. 8(6) 352–359
15_ Poullis A, Foster R, et al. Review article: faecal markers in the assessment of activity in infammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 675±681.
16_Kawashima K, Ishihara S, Yuki T, et al. Fecal calprotectin more accurately
predicts endoscopic remission of Crohnʼs disease than serological
biomarkers evaluated using balloon-assisted enteroscopy. Inflamm Bowel Dis
2017;23:2027–34.
17_Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I.
Surrogate markers of intestinal in¯ammation are predictive of
relapse in patients with in¯ammatory bowel disease. Gastroenterology
2000; 119(1): 15±22.

18_Lasson A, Stotzer PO, Öhman L, et al. The intra-individual variability of
faecal calprotectin: a prospective study in patients with active ulcerative
colitis. J Crohns Colitis. 2015;9:26–32.
19_Menees S , Powell C , Kurlander J et al. A meta-analysis of the utility of
C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and
fecal lactoferrin to exclude infl ammatory bowel disease in adults with IBS .
Am J Gastroenterol 2015 ; 110 : 444 – 54.
20_Lozoya Angulo ME, De las Heras Gómez I, Martinez Villanueva M, Noguera
Velasco JA, Avilés PLaza F. Calprotectina fecal, marcador eficaz en la
diferenciación de enfermedades inflamatorias intestinales y trastornos
funcionales gastrointestinales. Gastroenterol Hepatol. 2017;40(3):125–31.
